Search Results

You are looking at 241 - 250 of 1,243 items for :

  • Refine by Access: All x
Clear All
Full access

Lina Jansen, Daniel Boakye, Elizabeth Alwers, Prudence R. Carr, Christoph Reissfelder, Martin Schneider, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

characteristics (Charlson comorbidity score and regular use of statins and nonsteroidal anti‐inflammatory drugs [NSAIDs], including aspirin), tumor-related characteristics (year of diagnosis, cancer stage, and cancer site), and treatment characteristics (surgery

Full access

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven

cancer can be treated with surgery with or without (neo)adjuvant chemo(radio)therapy. Potentially curable esophageal cancer can also be treated with definitive chemoradiotherapy. Metastatic disease is treated mainly with systemic therapy but also with

Full access

Hiram S. Cody III and Kimberly J. Van Zee

III trial 10853 . Lancet 2000 ; 355 : 528 – 533 . 21 Kestin LL Goldstein NS Martinez AA . Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: Patterns of failure and 10

Full access

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

distant metastatic site was seen. The patient received adjuvant concurrent chemotherapy and radiation with 6 cycles of weekly intravenous carboplatin (area under the curve, 2) and paclitaxel at 50 mg/m 2 . Four weeks after surgery she received 63 Gy of

Full access

Elisabeth Kenne Sarenmalm, Salmir Nasic, Cecilia Håkanson, Joakim Öhlén, Eva Carlsson, Monica E. Pettersson, and Richard Sawatzky

-14). Sample and Setting The study sample was included in a large person-centered information and communication intervention among patients scheduled for elective CRC surgery. Patients were consecutively enrolled, and data were collected presurgery, including

Full access

Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill

therapy. A small proportion of patients with recurrent ovarian cancer may also be candidates for secondary cytoreductive surgery (SCS) for low-volume, isolated disease, which may be missed without routine surveillance imaging. Recent data suggest that

Full access

Laura M. Spring, Yael Bar, and Steven J. Isakoff

Use of neoadjuvant therapy (NAT) for operable breast cancer has increased significantly over the past several years. Initially, interest in NAT centered around operability and improving eligibility for breast-conserving surgery. 1 Later, the

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

reduction agents/strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. However, women and their physicians who are considering interventions to reduce risk for breast cancer must balance the demonstrated benefits with

Full access

Corbin D. Jacobs, Daniel J. Rocke, Russel R. Kahmke, Hannah Williamson, Gita Suneja, and Yvonne M. Mowery

diagnosed with invasive nonmetastatic ARSCC between 2010–2014 were identified. Exclusion criteria included prior malignancy, no/unknown surgery, unknown receipt of RT, RT dose <50 Gy or >80 Gy, RT fractions >68, T1–2N0 disease without identifiable NCCN

Full access

Dayna Crawford, Brook Blackmore, Jeremy Ortega, and Erica Williams

Society Facts and Figures 2018). Early detection is increasing with nearly 45% of colon cancers diagnosed as stage I/II (Sarah Cannon Cancer Registry 2015). Treatment for early stage I/II colon cancer patients usually involves surgery then surveillance. On